Cargando…

Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis

BACKGROUND: Inhibition of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) is a novel choice for the treatment of renal anemia, and an oral HIF-PH inhibitor roxadustat was approved for renal anemia. Roxadustat has high affinity to thyroid hormone receptor beta, which may affect thyroid hormone h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ichii, Mitsuru, Mori, Katsuhito, Miyaoka, Daichi, Sonoda, Mika, Tsujimoto, Yoshihiro, Nakatani, Shinya, Shoji, Tetsuo, Emoto, Masanori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981856/ https://www.ncbi.nlm.nih.gov/pubmed/33743638 http://dx.doi.org/10.1186/s12882-021-02304-2

Ejemplares similares

Associations of Serum Insulin-Like Growth Factor 1 with New Cardiovascular Events and Subsequent Death in Hemodialysis Patients: The DREAM Cohort
por: Nakaya, Rino, et al.
Publicado: (2022)

Cardiothoracic Ratio as a Predictor of Cardiovascular Events in a Cohort of Hemodialysis Patients
por: Okute, Yujiro, et al.
Publicado: (2017)

Association between Levocarnitine Treatment and the Change in Knee Extensor Strength in Patients Undergoing Hemodialysis: A Post-Hoc Analysis of the Osaka Dialysis Complication Study (ODCS)
por: Matsufuji, Shota, et al.
Publicado: (2022)

Nutritional Status Association With Sarcopenia in Patients Undergoing Maintenance Hemodialysis Assessed by Nutritional Risk Index
por: Kurajoh, Masafumi, et al.
Publicado: (2022)

Low Free Triiodothyronine Level as a Predictor of Cardiovascular Events and All-Cause Mortality in Patients Undergoing Hemodialysis: The DREAM Cohort
por: Yamazaki, Yuko, et al.
Publicado: (2021)

Association of Reduced Free T3 to Free T4 Ratio with Lower Serum Creatinine in Japanese Hemodialysis Patients
por: Inaba, Masaaki, et al.
Publicado: (2021)

Association of Zinc Deficiency with Development of CVD Events in Patients with CKD
por: Nakatani, Shinya, et al.
Publicado: (2021)

Association between Serum Zinc and Calcification Propensity (T(50)) in Patients with Type 2 Diabetes Mellitus and In Vitro Effect of Exogenous Zinc on T(50)
por: Nakatani, Shinya, et al.
Publicado: (2020)

Oxidative Stress and Inflammation as Predictors of Mortality and Cardiovascular Events in Hemodialysis Patients: The DREAM Cohort
por: Sasaki, Keyaki, et al.
Publicado: (2021)

Reduced Risk of Progression from Non-Severe to Severe COVID-19 in Hospitalized Dialysis Patients by Full COVID-19 Vaccination
por: Ichii, Mitsuru, et al.
Publicado: (2022)

Impact of diabetes on sarcopenia and mortality in patients undergoing hemodialysis
por: Mori, Katsuhito, et al.
Publicado: (2019)

Linagliptin monotherapy compared with voglibose monotherapy in patients with type 2 diabetes undergoing hemodialysis: a 12-week randomized trial
por: Mori, Katsuhito, et al.
Publicado: (2016)

Xanthine Oxidoreductase Inhibitor Use Associated With Reduced Risk of Sarcopenia and Severe Sarcopenia in Patients Undergoing Hemodialysis
por: Kurajoh, Masafumi, et al.
Publicado: (2022)

Roxadustat: Not just for anemia
por: Zhu, Xiaoyu, et al.
Publicado: (2022)

Associations of time-dependent changes in phosphorus levels with cardiovascular diseases in patients undergoing hemodialysis: results from the Japan Dialysis Active Vitamin D (J-DAVID) randomized clinical trial
por: Koshi-Ito, Eri, et al.
Publicado: (2022)

Roxadustat treatment for erythropoiesis-stimulating agent-hyporesponsive anemia in maintenance hemodialysis patients
por: Song, Jie, et al.
Publicado: (2023)

Dialysate calcium, alfacalcidol, and clinical outcomes: A post-hoc analysis of the J-DAVID trial
por: Iseki, Kunitoshi, et al.
Publicado: (2022)

Significant association between glycemic status and increased estimated postglomerular resistance in nondiabetic subjects – study of inulin and para-aminohippuric acid clearance in humans
por: Yasumoto, Mari, et al.
Publicado: (2015)

Xanthine oxidoreductase activity is associated with serum uric acid and glycemic control in hemodialysis patients
por: Nakatani, Ayumi, et al.
Publicado: (2017)

Roxadustat for treatment of erythropoietin-hyporesponsive anemia in a hemodialysis patient: A case report
por: Yu, Wei-Hong, et al.
Publicado: (2020)

Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients
por: Akizawa, Tadao, et al.
Publicado: (2020)

Successful alternative vaccination with BNT162b2 mRNA COVID-19 vaccine for new-onset IgA vasculitis after receiving mRNA-1273—case report
por: Morioka, Fumiyuki, et al.
Publicado: (2022)

Cinacalcet may suppress kidney enlargement in hemodialysis patients with autosomal dominant polycystic kidney disease
por: Nakatani, Shinya, et al.
Publicado: (2021)

Short-Term Dapagliflozin Administration in Autosomal Dominant Polycystic Kidney Disease—A Retrospective Single-Arm Case Series Study
por: Morioka, Fumiyuki, et al.
Publicado: (2023)

Non-mercaptalbumin, Oxidized Form of Serum Albumin, Significantly Associated with Renal Function and Anemia in Chronic Kidney Disease Patients
por: Nakatani, Shinya, et al.
Publicado: (2018)

Effects of fetuin-A-containing calciprotein particles on posttranslational modifications of fetuin-A in HepG2 cells
por: Uedono, Hideki, et al.
Publicado: (2021)

Effects of alfacalcidol on cardiovascular outcomes according to alkaline phosphatase levels in the J-DAVID trial
por: Oka, Tatsufumi, et al.
Publicado: (2022)

Roxadustat for CKD-related Anemia in Non-dialysis Patients
por: Coyne, Daniel W., et al.
Publicado: (2020)

The role of roxadustat in chronic kidney disease patients complicated with anemia
por: Liu, Jie, et al.
Publicado: (2023)

Plasma soluble leptin receptor levels are associated with pancreatic β‐cell dysfunction in patients with type 2 diabetes
por: Morioka, Tomoaki, et al.
Publicado: (2017)

Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis
por: Provenzano, Robert, et al.
Publicado: (2020)

A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study
por: Charytan, Chaim, et al.
Publicado: (2021)

Effects of Roxadustat on the Anemia and Iron Metabolism of Patients Undergoing Peritoneal Dialysis
por: Hirai, Keiji, et al.
Publicado: (2021)

Iron Parameters in Patients Treated with Roxadustat for Anemia of Chronic Kidney Disease
por: Ganz, Tomas, et al.
Publicado: (2023)

Plasma homocysteine and cerebral small vessel disease as possible mediators between kidney and cognitive functions in patients with diabetes mellitus
por: Sonoda, Mika, et al.
Publicado: (2017)

Long-Term Effects of High-Dose Tolvaptan for Autosomal Dominant Polycystic Kidney Disease Patients
por: Nakatani, Shinya, et al.
Publicado: (2020)

New-onset kidney biopsy-proven IgA vasculitis after receiving mRNA-1273 COVID-19 vaccine: case report
por: Nakatani, Shinya, et al.
Publicado: (2022)

Roxadustat for CKD Anemia – Starting the Jigsaw Puzzle, What Will the Finished Picture Show?
por: Winkelmayer, Wolfgang C., et al.
Publicado: (2021)

Efficacy of Roxadustat on anemia and residual renal function in patients new to peritoneal dialysis
por: Wu, Tong, et al.
Publicado: (2022)

Phase 3 Study of Roxadustat to Treat Anemia in Non–Dialysis-Dependant CKD
por: Akizawa, Tadao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uhnu2s80tqbf3cmtvvbv8a41sd